Tag: 上海后花园AJ

Posted in nrbeeohtbedc

Bill To Give Attorney General Power To Prosecute Local Cases Advances In Senate

first_imgTheStateHouseFile.comINDIANAPOLIS—County prosecutors and defense attorneys were united Tuesday in opposition to legislation that would allow the attorney general’s office to pursue criminal cases that locals decline.In spite of overwhelming testimony against Senate Bill 436, the proposed legislation passed the Senate Corrections and Criminal Code Committee by a 6-3 vote. It now heads to the full Senate for action.Sen. Michael Young, R-Indianapolis, right, chairs the Corrections and Criminal Code Committee and authored the bill allowing the attorney general’s office to assume jurisdiction over local prosecutors in some cases. Photo by Victoria Ratliff, TheStatehouseFile.com.The amended version of the bill, authored by Sen. Michael Young, R-Indianapolis, would allow the state’s attorney general to name a special prosecutor to pursue criminal cases when local prosecutors decide against filing charges.David Powell, a senior council of Prosecuting Attorney’s Council, was adamant in his opposition to the bill.“The one thing I can say without hesitation, having been involved for almost four decades in this business, is prosecutorial discussion is the holy grail,” Powell said, adding that it should be up to the local prosecutor to decide what to charge or not charge.Much of the discussion about the bill focused on the decision last year by Marion County Prosecutor Ryan Mears to not prosecute people arrested with small amounts of marijuana in their possession.David Powell of the Indiana Prosecuting Attorneys Council opposed legislation that would usurp the authority of local prosecutors. Photo by Victoria Ratliff, TheStatehouseFile.com.Michael Moore of Indiana Public Defender Council said that SB 436 overrides the voices of local voters who might have selected a prosecutor because he or she declined to prosecute certain low-level crimes. He noted that many times people of color or living in poverty are disproportionately affected by the prosecution of low-level crimes.Young said he began working on the bill after learning some prosecutors are failing to pursue some crimes.“What gives me concern is this growing trend throughout the country where prosecutors aren’t simply prosecuting crimes as a whole, as a policy,” Young said. Some examples he gave were damage to one’s property by rioting and stealing less than $900 from a business or person among other crimes.During the hearing, 15 people testified and only Parvonay Stover of the attorney general’s office wasn’t opposed to it. She said the attorney general is neutral on it.“That being said, if the General Assembly decides to move ahead with this concept, then we are ready and willing to help in whatever way we can,” Stover said. “But we think it’s merely a band aid to the underlying problem.” She did not elaborate.Katie Blair, director of Advocacy and Public Policy for the American Civil Liberties Union of Indiana, said the legislation would undermine the power of voters to hold local prosecutors accountable for their actions.Sen. Karen Tallian, D-Ogden Dunes, said that she found the bill to be “amazingly wrong” and unconstitutional. She is a member of the committee and voted against the bill.“It’s going to be incredibly hard to determine what is an announced categorical refusal versus a practice that may be done quietly, and not be announced,” she said. “I think one of the things this bill will do is to encourage prosecutors to do something and not make it transparent.”FOOTNOTE: Lacey Watt is a reporter for TheStatehouseFile.com, a news website powered by Franklin College journalism students. By Lacey Watt FacebookTwitterCopy LinkEmailSharelast_img read more

Continue Reading Bill To Give Attorney General Power To Prosecute Local Cases Advances In Senate
Posted in qygofqspskjp

COMPETITION: WIN A SPOOKY FAMILY OVERNIGHT HALLOWEEN STAY AT GARTAN OUTDOOR CENTRE

first_imgChange The Scene this Halloween at GartanThe All New Devil’s Realm has relocated to the Gartan Outdoor Centre for 2015 which makes for a perfect overnight destination for mid-term break for those how dare!The Devils Realm is a professional, frightening walk through the forest – this event is intense with effects that are intended to increase the realism of the experience.Stay if you DARE! Gartan are offering superb offers for those who wish to stay overnight, with dorm B&B €18pp, Private 4 Bed Room with shared bathroom only €60 in total and Private Ensuite Room which can accommodate up to 4 people only €75.Most bedrooms overlook the stunning Gartan Lake, and the dining area for dinner & breakfast also has unrestricted, breath taking views of this beautiful lake. For those just wishing for an adventurous family break without any frights, Gartan are offering excellent optional extras such as Kayaking, Canadian Canoeing, Gorge Walking, Hill walking and Much More – where else would you have so much choice this Halloween Break?Packages are available to include activities, lunch and dinner. Tickets for the Devils Realm, B&B are also available. For further information call Gartan now – limited availability 074 91 37032 or email [email protected] note, the Devils Realm event is not suitable for under 12’s, however younger folk can stay and take part in other activities. For more details contact Gartan OETC. NOW WOULD YOU LIKE TO WIN a family pass to the Devils Realm & overnight B&B for a family of 4? If so, simply email [email protected] with your full name, address, contact number and answering the following question: What sort of canoeing can you do at Gartan?Closing date for entries is Thursday October 22 at noon. Usual Donegal Daily rules apply. No cash alternative. Break must be taken this Halloween. COMPETITION: WIN A SPOOKY FAMILY OVERNIGHT HALLOWEEN STAY AT GARTAN OUTDOOR CENTRE was last modified: October 15th, 2015 by John2Share this:Click to share on Facebook (Opens in new window)Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Reddit (Opens in new window)Click to share on Pocket (Opens in new window)Click to share on Telegram (Opens in new window)Click to share on WhatsApp (Opens in new window)Click to share on Skype (Opens in new window)Click to print (Opens in new window) Tags:competitiondevil’s realmdonegalgartanoutdoor centrelast_img read more

Continue Reading COMPETITION: WIN A SPOOKY FAMILY OVERNIGHT HALLOWEEN STAY AT GARTAN OUTDOOR CENTRE
Posted in votwpslwaksb

Swapping daily pills for monthly shots could transform HIV treatment and prevention

first_imgIn a clinical trial in Mfekayi, South Africa, counselors counted antiretroviral pills to make sure participants took medications as directed. Click to view the privacy policy. Required fields are indicated by an asterisk (*) Swapping daily pills for monthly shots could transform HIV treatment and prevention By Jon CohenAug. 22, 2018 , 11:30 AM Sign up for our daily newsletter Get more great content like this delivered right to you! Country Emailcenter_img New results are raising hopes for easing one challenge of living with HIV: the need to take daily pills for life, both to ward off AIDS and to lower the risk of transmitting the virus to others. Missing doses can also foster the emergence of HIV strains with drug resistance, a danger both to the person receiving treatment and, if those strains spread, to entire populations. Now, a large-scale study has shown over 48 weeks that monthly injections of two long-acting anti-HIV drugs work just as well as taking daily pills.ViiV Healthcare, a London-based collaboration between GlaxoSmithKline and Pfizer, revealed the highly anticipated findings in a press release on 15 August. This shareholder announcement, required by regulatory agencies to inform investors, offered scant data. But it was welcome news to other researchers studying long-acting anti-HIV medication schemes—and to clinicians who think they could transform both treatment and prevention of HIV infections.Anton Pozniak, an HIV/AIDS clinician at Chelsea and Westminster Hospital in London, says long-acting injections could help HIV-infected people who have “pill fatigue,” difficulty swallowing the medication, or psychological issues that make it hard to cope with a daily reminder that they have a deadly virus. He calls the results “a fantastic development” but adds, “We still have a way to go.” Even if these injectables win regulatory approval, many practical questions remain about their cost, the impact of missing shots, inflammation at injection sites, and the burden on health care systems of providing monthly intramuscular injections. Country * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe J. Cohen/Science The phase III study, called Antiretroviral Therapy as Long-Acting Suppression (ATLAS), is testing an experimental drug, cabotegravir, made by ViiV, and rilpivirine, a licensed medicine from Janssen Sciences Ireland UC in Dublin, in 618 HIV-infected people from 13 countries. All had fully suppressed the virus for at least 6 months with oral drugs. Half stayed on daily pills, while the others received an injection into the buttocks of each drug once a month. Viral suppression was the same in both groups, ViiV’s statement says.Kimberly Smith, who heads R&D for ViiV from Durham, North Carolina, says the injectables could make it easier for clinicians to know for certain that patients are adhering to their treatment. Studies have shown that about 30% of HIV-infected people have difficulty doing so at some point; even those taking just a single multidrug pill a day miss doses. Smith, an HIV/AIDS clinician before she came to ViiV, says, “I experienced having patients die … because they just couldn’t get over that hurdle of taking that pill every day.”Long-duration anti-HIV drugs could also protect uninfected people at risk of getting the virus. Such people are even more reluctant to take daily pills, as required for so called pre-exposure prophylaxis (PrEP). Raphael Landovitz, a clinician at the University of California, Los Angeles, who studies long-acting drugs for PrEP, says the ATLAS data are “incredibly encouraging and exciting” and are “certainly reassuring” to people doing similar prevention work.Landovitz is collaborating on studies of how long-acting injectables, including cabotegravir and, separately, a monoclonal antibody developed by the U.S. National Institute of Allergy and Infectious Diseases (NIAID) in Bethesda, Maryland, improve adherence in people on PrEP. Also underway is a phase III study of the ATLAS regimen in HIV-infected people who have never taken any antiretrovirals. It addresses the possibility that patients in the original trial, who were on oral drugs beforehand, might harbor resistant virus that could undermine the effectiveness of the injections. And a trial called ATLAS 2 will ask whether the injectables can effectively suppress HIV if given only once every 8 weeks.Other long-acting HIV treatments at earlier phases of clinical testing include injections of a new Gilead Sciences drug that cripples the making of HIV’s capsid protein, a novel target. Researchers also are exploring long-acting alternatives to injections, including a Merck & Co. pill that inhibits HIV’s reverse transcriptase enzyme for up to 10 days. In the future, researchers hope to extend the effect of antiretrovirals with slow-release skin implants or polymer-based pills that slowly dissolve in the stomach.If both phase III studied have positive results, the drugmakers could apply for regulatory approval next year. But Landovitz cautions that many “nuanced questions” remain about how to use these long-acting drugs. What’s the optimal dose and timing of injections? What resistance mutations might emerge and how would they hamper the effectiveness of conventional oral drugs?Although a long-acting drug regimen can be a blessing, Smith says, “it has the potential to be a curse if a person disappears.” Because the drugs metabolize so slowly, they can have an unusually long pharmacological “tail,” their presence steadily declining in blood and tissues for a year or longer, which could allow drug-resistant strains of HIV to flourish.It’s anyone’s guess what the long-acting drugs would cost and whether developing countries could afford them. It’s also unclear how many people will opt for injections over pills. So only real-world experience will prove whether long-acting interventions will be “a niche or transformative,” Landovitz says. As NIAID head Anthony Fauci puts it, “This is not the end game, but it’s an important first step.”last_img read more

Continue Reading Swapping daily pills for monthly shots could transform HIV treatment and prevention